Urologic Neoplasms
Recent clinical, regulatory, research and industry developments relating to this disease.
Applications of artificial intelligence in urologic oncology.
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q4 2026.
- Q4 2026A Phase 2 Clinical Study to Assess Efficacy of Induction Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer: PRIAM
- Q4 2026A Phase 2 Trial in Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
- Q4 2026A Study of the Clinical Application of [18F]RCCB6 PET/ CT Imaging in the Diagnosis of Kidney Cancer
Clinical MilestonesViewHide
- 2026-08-21A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 AlterationsResults posted
- 2026-04-14A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)Results posted
- 2026-07-15A Phase 2 Trial in Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without RelatlimabResults expected Q4 2026
- 2025-12-31A Study of the Clinical Application of [18F]RCCB6 PET/ CT Imaging in the Diagnosis of Kidney CancerResults expected Q4 2026
- 2025-12-08A Phase 2 Clinical Study to Assess Efficacy of Induction Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer: PRIAMResults expected Q4 2026
- 2026-08-21ClinicalA Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 AlterationsResults posted
- 2026-07-15ClinicalA Phase 2 Trial in Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without RelatlimabResults expected Q4 2026
- 2026-04-14ClinicalA Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)Results posted
- 2026-02-20ClinicalA Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial CancerTerminated
- 2025-12-31ClinicalA Study of the Clinical Application of [18F]RCCB6 PET/ CT Imaging in the Diagnosis of Kidney CancerResults expected Q4 2026
- 2025-12-08ClinicalA Phase 2 Clinical Study to Assess Efficacy of Induction Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer: PRIAMResults expected Q4 2026
Research-associated treatments
Drugs and agents co-studied with this disease across the research literature — associative, not necessarily established treatments. Number shows shared papers.
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Urologic Neoplasms3
- Antibodies, Monoclonal1
- Antineoplastic Agents1
- Antineoplastic Combined Chemotherapy Protocols1
- Artificial Intelligence1
- Biomarkers, Tumor1
- Breast Neoplasms1
- Carcinoma, Transitional Cell1
Leading journals6
- The New England journal of medicine5
- Cancer2
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology2
- Clinical cancer research : an official journal of the American Association for Cancer Research1
- European urology oncology1
- Investigative and clinical urology1
Leading researchers8
- Loriot Y4
- Petrylak DP4
- Necchi A3
- Park SH3
- Powles T3
- Bellmunt J2
- Castellano D2
- Duran I2
Affiliations (unnormalised)6
- Asan Medical Center1
- Barbara Ann Karmanos Cancer Institute1
- Bavarian Center for Cancer Research (Bayerisches Zentrum für Krebsforschung1
- Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD)1
- Centre Georges Francois Leclerc1
- Charité Comprehensive Cancer Center1
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Urologic neoplasms are tumors or cancers arising in the urinary tract in either males or females. The supplied literature framing treats this as a broad urologic oncology category that includes diseases such as bladder, prostate, and kidney cancers.
The grounding supports a neoplastic process in the urinary tract, with literature emphasis on pathology, blood-based markers, and genetics. Review material also highlights circulating tumor DNA as a source of prognostic and predictive information, reflecting tumor biology that can be monitored for progression and drug resistance.
The supplied grounding supports treatment at the modality and drug-class level rather than a single uniform regimen. Co-studied therapies include platinum-based chemotherapy, gemcitabine, pembrolizumab, and enfortumab vedotin, indicating use of cytotoxic chemotherapy, immune checkpoint inhibition, and antibody-drug conjugate approaches in urologic oncology.
AI-generated summary grounded in MeSH and 2 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Tumors or cancer of the URINARY TRACT in either the male or the female.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.